Assenagon Asset Management S.A. Invests $8.56 Million in Haemonetics Corporation $HAE

Assenagon Asset Management S.A. bought a new position in shares of Haemonetics Corporation (NYSE:HAE) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 175,574 shares of the medical instruments supplier’s stock, valued at approximately $8,557,000. Assenagon Asset Management S.A. owned about 0.36% of Haemonetics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of HAE. Dynamic Technology Lab Private Ltd purchased a new position in shares of Haemonetics during the first quarter valued at about $468,000. Boston Partners boosted its stake in Haemonetics by 2.2% during the second quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock valued at $40,660,000 after buying an additional 11,738 shares during the last quarter. AQR Capital Management LLC grew its holdings in Haemonetics by 591.6% during the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after buying an additional 149,325 shares in the last quarter. Norges Bank bought a new stake in Haemonetics in the 2nd quarter worth approximately $36,822,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Haemonetics by 7.5% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,907 shares of the medical instruments supplier’s stock worth $963,000 after acquiring an additional 898 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

Shares of NYSE:HAE opened at $80.21 on Friday. The firm’s 50 day simple moving average is $68.43 and its 200-day simple moving average is $64.84. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The firm has a market cap of $3.75 billion, a PE ratio of 23.45, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same period in the prior year, the firm earned $1.12 earnings per share. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. JPMorgan Chase & Co. upped their target price on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Mizuho increased their price target on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday. Barrington Research boosted their price objective on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $84.10.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.